A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia - Fadlyana, Eddy; Rusmil, Kusnandi; Tarigan, Rodman; Rahmadi, Andri Reza; Prodjosoewojo, Susantina; Sofiatin, Yulia; Khrisna, Citra V.; Sari, Rini Mulia; Setyaningsih, Lilis; Surachman, Fikrianti; Bachtiar, Novilia Sjafri; Sukandar, Hadyana; et al. (Vaccine, 2021)
Keywords: Adult; Adults; Adverse events; Allergy and Immunology; Aluminum; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Assaying; blood; Chronic illnesses; Clinical trials; Coronaviruses; COVID-19; COVID-19 infection; COVID-19 Vaccines; Deactivation; Dosage; Double-Blind Method; Efficacy; Enzyme-linked immunosorbent assay; Epidemics; Evaluation; Humans; Immunogenicity; Immunogenicity, Vaccine; Immunoglobulin G; Indonesia; Indonesia - epidemiology; Infectious diseases; Influenza; injection site; Laboratories; Life sciences; Neutralization; neutralization tests; pain; pandemic; Pandemics; Placebos; Pneumonia; Safety; SARS-CoV-2; SARS-CoV-2 Inactivated Vaccine; Seroconversion; Severe acute respiratory syndrome coronavirus 2; Surveillance; vaccination; Vaccines; Vaccines, Inactivated - adverse effects; Viral diseases; Viruses; Indonesia; China; COVID-19; Immunogenicity; SARS-CoV-2 Inactivated Vaccine; IgG; Efficacy; SARS; Adults; Safety; ELISA; GMT; rRT-PCR; WHO; World Health Organization; Geometric Mean Titer; Immunoglobulin G; Enzyme Link Immunoassay; Coronavirus Disease 2019; Real-time Reverse Transcriptase-PCR; Severe Acute Respiratory Syndrome